CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Fungal nail infection (onychomycosis) - Evidence
Evidence on oral terbinafine for candidal onychomycosis
There is weak evidence that terbinafine is effective in Candida onychomycosis.
- An open-label uncontrolled trial (n = 20) found that oral terbinafine, 250 mg each day for 16 weeks resulted in a 60% clinical and mycological cure rate at 48 weeks [Segal et al, 1996].
- A small randomized controlled trial (RCT) that investigated the efficacy of oral terbinafine for the treatment of mixed onychomycosis (where a third of people had candidal infection) suggested that terbinafine may be an effective treatment for Candida onychomycosis [Lebwohl et al, 2001].
© NHS Institute for Innovation and Improvement